Class information for:
Level 1: TUMOR INFILTRATING LYMPHOCYTES//ADOPTIVE IMMUNOTHERAPY//AUTOLYMPHOCYTE THERAPY

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
10495 992 35.1 78%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
151 22214 IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TUMOR INFILTRATING LYMPHOCYTES Author keyword 18 18% 9% 94
2 ADOPTIVE IMMUNOTHERAPY Author keyword 14 14% 9% 90
3 AUTOLYMPHOCYTE THERAPY Author keyword 5 63% 1% 5
4 IMMUNO CELL THERAPY Author keyword 4 75% 0% 3
5 SURG FF50 Address 3 57% 0% 4
6 IN VITRO SENSITIZATION Author keyword 3 100% 0% 3
7 T CELL MEMORY Author keyword 3 100% 0% 3
8 MOL TUMOR IMMUNOL Address 3 22% 1% 11
9 AUTOLOGOUS TUMOR Author keyword 3 42% 1% 5
10 TIL Author keyword 3 15% 2% 16

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 TUMOR INFILTRATING LYMPHOCYTES 18 18% 9% 94 Search TUMOR+INFILTRATING+LYMPHOCYTES Search TUMOR+INFILTRATING+LYMPHOCYTES
2 ADOPTIVE IMMUNOTHERAPY 14 14% 9% 90 Search ADOPTIVE+IMMUNOTHERAPY Search ADOPTIVE+IMMUNOTHERAPY
3 AUTOLYMPHOCYTE THERAPY 5 63% 1% 5 Search AUTOLYMPHOCYTE+THERAPY Search AUTOLYMPHOCYTE+THERAPY
4 IMMUNO CELL THERAPY 4 75% 0% 3 Search IMMUNO+CELL+THERAPY Search IMMUNO+CELL+THERAPY
5 IN VITRO SENSITIZATION 3 100% 0% 3 Search IN+VITRO+SENSITIZATION Search IN+VITRO+SENSITIZATION
6 T CELL MEMORY 3 100% 0% 3 Search T+CELL++MEMORY Search T+CELL++MEMORY
7 AUTOLOGOUS TUMOR 3 42% 1% 5 Search AUTOLOGOUS+TUMOR Search AUTOLOGOUS+TUMOR
8 TIL 3 15% 2% 16 Search TIL Search TIL
9 CYTOTOXIC T CELL CLONE 2 67% 0% 2 Search CYTOTOXIC+T+CELL+CLONE Search CYTOTOXIC+T+CELL+CLONE
10 MCA 105 2 67% 0% 2 Search MCA+105 Search MCA+105

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 AUTOLOGOUS TUMOR 28 30% 8% 80
2 HUMAN METASTATIC MELANOMAS 22 60% 2% 24
3 INFILTRATING LYMPHOCYTES 17 11% 15% 144
4 LYMPH NODE CELLS 16 26% 5% 53
5 INVITRO SENSITIZATION 14 60% 2% 15
6 ANTI CD3 6 19% 3% 26
7 AUTOLOGOUS HUMAN MELANOMA 4 30% 1% 12
8 ANTI CD28 MONOCLONAL ANTIBODIES 4 75% 0% 3
9 INTRACEREBRAL TUMORS 4 41% 1% 7
10 VACCINE PRIMED LYMPHOCYTES 3 57% 0% 4

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
TUMOR-INFILTRATING LYMPHOCYTES - THEIR PHENOTYPE, FUNCTIONS AND CLINICAL USE 1994 76 60 52%
T-CELL RECOGNITION OF HUMAN TUMORS - IMPLICATIONS FOR MOLECULAR IMMUNOTHERAPY OF CANCER 1993 113 134 35%
Adoptive cellular therapy 2000 65 85 26%
MHC CLASS-II RESTRICTED TUMOR-ANTIGENS AND THE ROLE OF CD4(+) T-CELLS IN CANCER-IMMUNOTHERAPY 1994 89 29 24%
Current status of adoptive immunotherapy of cancer 1996 38 99 30%
On the road to a tumor cell vaccine: 20 years of cellular immunotherapy 2004 49 203 14%
CELLULAR IMMUNE-RESPONSE AGAINST AUTOLOGOUS HUMAN-MALIGNANT MELANOMA - ARE INVITRO STUDIES PROVIDING A FRAMEWORK FOR A MORE EFFECTIVE IMMUNOTHERAPY 1990 68 99 46%
CD4(+) T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection 2000 71 269 17%
T-CELL CLONES THAT REACT AGAINST AUTOLOGOUS HUMAN TUMORS 1990 50 39 56%
Current status of adoptive immunotherapy of malignancies 2002 15 82 32%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SURG FF50 3 57% 0.4% 4
2 MOL TUMOR IMMUNOL 3 22% 1.1% 11
3 SURG FF5 2 67% 0.2% 2
4 UNITA IMMUNOTER IA CELLULARE 2 67% 0.2% 2
5 RIKEN CELL BANK 1 21% 0.6% 6
6 OREGON CANC 1 14% 0.7% 7
7 MD ANDERSON CANC IMMUNOL 1 40% 0.2% 2
8 AFFILIATD HOSP 1 1 50% 0.1% 1
9 CANC HOSP E 1 50% 0.1% 1
10 DIPARTIMENTO ONCOL GENET BIOL 1 50% 0.1% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000246941 CD3 ZETA//ORAL BIOL ORAL MED//ZETA CHAIN
2 0.0000216893 INTERLEUKIN 2//LYMPHOKINE ACTIVATED KILLER CELLS//RECOMBINANT INTERLEUKIN 2
3 0.0000181862 TUMOR BEARING STATE//AUTOIMMUNOTHERAPY//CD8 CELL REACTIVITY
4 0.0000164237 ADV CELL MOL THER Y//SHUNDE PEOPLES HOSP//TUMOR VACCINE
5 0.0000137285 UNITA OPERAT ASSISTENZIALE GINECOL ONCOL//CD1A//CDLA
6 0.0000134008 IMMUNE SUPPRESSOR CELLS//IRX 2//SERV 151Z2
7 0.0000132234 ANTIGEN PROCESSING MACHINERY//BIOQUIM BIOL MOL INMUNOL 3//HLA CLASS I
8 0.0000130662 OK 432//OK432//PROD LIFECYCLE MED INFORMAT
9 0.0000108447 CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1
10 0.0000096031 SPECTRATYPING//CDR3//T CELL REPERTOIRE